Evidence map›Paper›PMID 12626459›Full record

ArticleClinical and diagnostic laboratory immunology2003

Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease.

Pong Kian Chua, Marian E Melish, Qigui Yu, Richard Yanagihara, Kara S Yamamoto, Vivek R Nerurkar

Open access · diamondAbstract read
In one paragraph

Article in Clinical and diagnostic laboratory immunology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 47 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Epigenetics in Kawasaki Disease.Frontiers in pediatrics · 2021
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Pong Kian ChuaRetrovirology Research Laboratory, Pacific Biomedical Research Center, University of Hawaii at Manoa, Honolulu, Hawaii 96822, USA.
Marian E Melish
Qigui Yu
Richard Yanagihara
Kara S Yamamoto
Vivek R Nerurkar
University of Hawaiʻi at Mānoa · USPacific Medical (China) · CN

Funding

WORLDWIDE EPIDEMIOLOGY &EPIZOOTIOLOGY OF HANTAVIRUSG12RR003061 · NCRR · UNIVERSITY OF HAWAII AT MANOA · PI NERURKAR, VIVEK RAMCHANDRA · 1986 to 2011
$32.3M
WILLINGNESS OF PRIMARY CARE PHYSICIANS TO ADOPT HANDHELD COMPUTINGP20RR011091 · NCRR · UNIVERSITY OF HAWAII AT MANOA · PI WRIGHT, CLAIRE · 1995 to 2009
$16.5M
ROLE OF PERIODONTAL DISEASE IN GESTATIONAL DIABETESU54RR014607 · NCRR · UNIVERSITY OF HAWAII AT MANOA · PI WRIGHT, TRICIA E · 1999 to 2008
$15.5M
NCRR NIH HHS G12 RR003061NCRR NIH HHS G12RR-003061NCRR NIH HHS G12 RR003061-20NCRR NIH HHS P20 RR011091NCRR NIH HHS P20 RR011091-11NCRR NIH HHS P20RR11091NCRR NIH HHS U54 RR014607-05
6 · The paper itself

Abstract

Kawasaki disease (KD) is an acute, self-limiting, multisystem vasculitis of unknown etiology affecting infants and young children. Unless treated promptly with high-dose intravenous gamma globulin and aspirin, patients frequently develop coronary aneurysms. Previously, matrix metalloproteinase 9 (MMP-9), which is secreted complexed to tissue inhibitor of metalloproteinase 1 (TIMP-1), has been implicated in abdominal aortic aneurysm formation. Since the clinical and pathological features of KD include inflammation and weakening of blood vessels, we analyzed acute- and convalescent-phase paired plasma or serum samples from 31 KD patients, 7 patients who did not completely meet the criteria for KD, and 26 non-KD controls (9 febrile and 17 afebrile patients) for pro-MMP-9 (92 kDa) enzyme activity by gelatin zymography and for active MMP-9 (83 kDa), pro-MMP-9, and TIMP-1 protein levels by enzyme-linked immunosorbent assay. Statistical analysis was performed by using Student t tests, linear regression, and the Wilcoxon rank-sum test. Markedly elevated pro-MMP-9 enzymatic activity, pro-MMP-9 protein levels, and TIMP-1 protein levels were found during the acute phase of illness in patients with clinically established KD and in patients who were suspected of having KD but did not meet all of the criteria. There was no significant difference in active MMP-9 levels. Furthermore, pro-MMP-9 and TIMP-1 protein levels were significantly elevated among KD patients, compared to those of febrile and afebrile non-KD controls. The significantly elevated pro-MMP-9 enzyme and protein levels during the acute phase of KD may reflect vascular remodeling or an inflammatory response to a microbial agent, suggesting a pathophysiological role for MMP-9 in coronary aneurysm formation.

Indexed as

Acute DiseaseChildEnzyme-Linked Immunosorbent AssayHumansMatrix Metalloproteinase 2Matrix Metalloproteinase 9Mucocutaneous Lymph Node SyndromeTissue Inhibitor of Metalloproteinase-1Matrix Metalloproteinase 2Matrix Metalloproteinase 9Tissue Inhibitor of Metalloproteinase-1

Identifiers

PMID12626459
PMCPMC150536
OpenAlexW2124228040

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.